ITIH4: A New Potential Biomarker of “Toxin Syndrome” in Coronary Heart Disease Patient Identified with Proteomic Method
Table 3
Comparison of before and after treatment in group B ().
Mass (Da)
Ave ± StdDev (B_Q)
Ave ± StdDev (B_H)
1616.74
32.83 ± 18.26
23.95 ± 12.74
0.033415
2209.31
29.04 ± 14.35
21.23 ± 10.27
0.022373
2881.04
49.8 ± 18.98
38.19 ± 10.15
0.010917
3207.37
56.15 ± 17.06
47.84 ± 12.01
0.023899
4053.87
60.23 ± 22.82
83.04 ± 42.14
0.010323
4266.31
35.94 ± 19.99
45.73 ± 19.4
0.020676
4279.95
18.9 ± 8.79
27.23 ± 23.79
0.025866
4817.85
20.34 ± 17.41
11.15 ± 7.93
0.012491
4936.10
21.91 ± 27.22
10.29 ± 3.94
0.02628
5066.25
25.87 ± 7.61
32.1 ± 11.2
0.019568
5248.63
21.01 ± 5.89
25.23 ± 8.04
0.025751
6378.01
47.98 ± 47.92
28.92 ± 10.34
0.045958
7833.86
10.85 ± 2.21
12.97 ± 4.82
0.040051
9064.40
30.36 ± 8.86
35.83 ± 10.12
0.012614
9290.26
907.98 ± 442.14
1126.48 ± 455.76
0.023601
Note: paired sample -test was used, 2-tailed, and was considered significant; Ave: peak area/intensity average; StdDev: standard deviation of the peak area/intensity average; B-Q: before treatment in group B; B-H: after treatment in group B; overstriking mass: unique to group B.
